{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": [], "KeywordList": [["macular degeneration", "ozone therapy", "retinopathy"]], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "23275905", "DateCompleted": {"Year": "2013", "Month": "01", "Day": "01"}, "DateRevised": {"Year": "2024", "Month": "05", "Day": "05"}, "Article": {"Language": ["eng"], "ELocationID": ["10.3980/j.issn.2222-3959.2012.06.11"], "ArticleDate": [{"Year": "2012", "Month": "12", "Day": "18"}], "Journal": {"ISSN": "2222-3959", "JournalIssue": {"Volume": "5", "Issue": "6", "PubDate": {"Year": "2012"}}, "Title": "International journal of ophthalmology", "ISOAbbreviation": "Int J Ophthalmol"}, "ArticleTitle": "Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study.", "Pagination": {"StartPage": "708", "EndPage": "713", "MedlinePgn": "708-13"}, "Abstract": {"AbstractText": ["To evaluate the effect of systemic ozonated major autohaemotherapy (O(3)-AHT) in patients affected by dry age related macular degeneration (AMD).", "This study was a randomized, controlled clinical study. One hundred and forty patients with the diagnosis of AMD in both eyes, with the study eye presenting dry AMD and soft drusen, were randomly assigned in a 1:1 ratio to either receive 27 major ozonated autohemotherapy treatments during 12-month period, or a standardized multi-vitamin therapy. Primary outcome was the change in best corrected visual acuity (mean logMar change) between the baseline and 6 and 12 months, end point of the study. In addition, to investigate the safety of prolonged ozonated autohaemotherapy, we measured the routine haematochemical parameters and biochemical oxidative stress values at baseline and after 12 months treatment time.", "The mean baseline best corrected visual acuity in study eyes was 0.36 in the treatment group and 0.38 in the control group (difference not statistically significant). At the primary endpoint, 6 months post-baseline, the mean logMAR change in the treated group improved by 0.1 and the values of the control group at the same time impaired by 0.2 respect to the baseline. Four percent and twenty-five percent of eyes in the group treated with O(3)-AHT gained 1 or more lines after 6 and 12 months respectively compared to 0% in the eyes which received no treatment (P<0.05 at 12 months). None of the treated patients experienced a loss in visual acuity in their study eye at 6 and 12 months, compared to 16% and 40 % of patients in the control group who lost 2 lines or more at 6 months and 12 months respectively (P<0.05 treated vs control group)). Major ozonated autohemotherapy was shown to be safe and well- tolerated by the patients. Moreover, the haematochemical parameters showed a decrease in the Reactive Oxygen Metabolites (300\u00b110.1 UCARR at 12 months compared to a baseline value of 380\u00b110.4 UCARR, P<0.05) and an increase in Biological Antioxidant Potential plasma values (2100\u00b134.8 micromoles/ C vitamin after 12 months compared to the baseline value of 1610\u00b136.2, P<0.05) in the treated patients when compared to the control group. This data suggests that major ozonated autohaemotherapy may exert a role in reducing oxidative stress by endogenously stimulating the production of antioxidant molecules.", "The results of this study suggests that major ozonated autohaemotherapy could be a safe and effective therapeutic option for high-risk patients with dry AMD, and that a series of such treatments could improve the natural course of AMD."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Surgery and Bioengineering, Policlinico Le Scotte, University of Siena, Siena, Italy."}], "Identifier": [], "LastName": "Borrelli", "ForeName": "Emma", "Initials": "E"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Diadori", "ForeName": "Angelica", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zalaffi", "ForeName": "Alessandro", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Bocci", "ForeName": "Velio", "Initials": "V"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Int J Ophthalmol", "NlmUniqueID": "101553860", "ISSNLinking": "2222-3959"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606\u20132617.", "ArticleIdList": ["18550876"]}, {"Citation": "Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull. 2008;85(1):127\u2013149.", "ArticleIdList": ["18334518"]}, {"Citation": "Kuno N, Fujii S. Dry age-related macular degeneration: recent progress of therapeutic approaches. Curr Mol Pharmacol. 2011;4(3):196\u2013232.", "ArticleIdList": ["21545354"]}, {"Citation": "Lin H, Xu H, Liang FQ, Liang H, Gupta P, Havey AN, Boulton ME, Godley BF. Mitochondrial DNA damage and repair in RPE associated with aging and age-related macular degeneration. Invest Ophtalmol Vis Sci. 2011;52(6):3521\u20133529.", "ArticleIdList": ["PMC3109040", "21273542"]}, {"Citation": "Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamin C and E, beta carotene and zinc for age-related macular degeneration and vision loss: AREDS report no.9. Arch Ophtalmol. 2001;119(10):1439\u20131452.", "ArticleIdList": ["PMC1472812", "11594943"]}, {"Citation": "Querques G, Avellis FO, Querques L, Bandello F, Souied EH. Age-related macular degeneration. Clin Ophtalmol. 2011;5:593\u2013601.", "ArticleIdList": ["PMC3102591", "21654887"]}, {"Citation": "Kokotas H, Grigoriadou M, Petersen MB. Age-related macular degeneration: genetic and clinical findings. Clin Chem Lab Med. 2011;49(4):601\u201316.", "ArticleIdList": ["21175380"]}, {"Citation": "Wehrli F, Steinbart H. Erfahrungen mit der hamatogen oxidation therapie (hot) Ars Medici. 1954;10:44\u201351."}, {"Citation": "Wolff HH. Die Behandlung peripherer Durchblutungsstorungen mit Ozon. Erfahr Hk. 1971;23:181\u2013184."}, {"Citation": "Tylicki L, Nieweglowski T, Biedunkiewicz B, Chamienia A, Debska-Slizien A, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int J artif Organs. 2003;26(4):297\u2013303.", "ArticleIdList": ["12757028"]}, {"Citation": "Riva Sanseverino E, Meduri RA, Pizzino A, Prantera M, Martini E. Effects of oxygen-ozone therapy on age-related degenerative retinal maculopathy. Panminerva Med. 1990;32(2):77\u201384.", "ArticleIdList": ["2250978"]}, {"Citation": "Bocci V. Dordrecht: the Netherlands: Kluwer Academic Publishers; 2002. Oxygen-ozone therapy. A critical evaluation; pp. 1\u2013427."}, {"Citation": "Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009;29(4):646\u2013682.", "ArticleIdList": ["19260079"]}, {"Citation": "Bocci V. The case for oxygen-ozonetherapy. Br J Biomed Sci. 2007;64(1):44\u201349.", "ArticleIdList": ["17444419"]}, {"Citation": "Bocci V. Biological and clinical effects of ozone. Has ozone therapy a future in medicine? Br J Biomed Sci. 56(4):270\u2013279.", "ArticleIdList": ["10795372"]}, {"Citation": "Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105:328\u2013331.", "ArticleIdList": ["6727672"]}, {"Citation": "Vassalle C, Boni C, Di Cecco P, Ndreu R, Di Cecco C. Automation and validation of a fast method for the assessment of in vivo oxidative stress level. Clin Chem Lab Med. 2006;44(11):1372\u20131375.", "ArticleIdList": ["17087652"]}, {"Citation": "Kakita H, Hussein MH, Daouda A, Kato T, Murai H, Sugiura T, Mizuno K, Yamada Y, Ito T, Fukuda S, Kato I, Suzuki S, Togari H. Total hydroperoxide and biological antioxidant potential in a neonatal sepsis model. Pediatr Res. 2006;60(6):675\u2013679.", "ArticleIdList": ["17065583"]}, {"Citation": "Yehoushua Z, Wang F, Rosenfeld PJ, Penha FM, Feuer WJ, Gregori G. Natural history of drusen morphology in age- related macular degeneration using spectral domain optical coherence tomography. Ophtalmology. 2011;118(12):2434\u20132441.", "ArticleIdList": ["PMC3189426", "21724264"]}, {"Citation": "Mathew RS, Delbaere K, Lord SR, Beaumont P, Vaegan, Madigan MC. Depressive symptoms and quality of life in people with age-related macular degeneration. Ophtalmic Physiol Opt. 2011;31(4):375\u2013380.", "ArticleIdList": ["21679317"]}, {"Citation": "Bocci V, Aldinucci C. Biochemical modifications induced in human blood by oxygenation ozonation. J Biochem Mol Toxicol. 2006;20(3):133\u2013138.", "ArticleIdList": ["16788956"]}, {"Citation": "Caglayan S, Bayer R. Effects of oxydative stress on erythrocyte deformability and fragility. Proc SPIE 2100. 1994;182:183\u2013189."}, {"Citation": "Giunta R, Coppola A, Luongo C, Sammartino A, Guastafierro S, Grassia A, Giunta L, Mascolo L, Tirelli A, Coppola L. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol. 2001;80(12):745\u2013748.", "ArticleIdList": ["11797116"]}, {"Citation": "Bocci V, Zanardi I, Travagli V. Ozone: a new medical drug in vascular diseases. Am J Cardiovasc Drugs. 2011;11(2):73\u201382.", "ArticleIdList": ["21446774"]}, {"Citation": "Tylicki L, Nieweglowski T, Biedunkiewicz B, Burakowski S, Rutkowski B. Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs- pilot study. Int J Artif Organs. 2001;24(2):79\u201382.", "ArticleIdList": ["11256512"]}, {"Citation": "Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci. 2008;1147:61\u201369.", "ArticleIdList": ["PMC2605641", "19076431"]}, {"Citation": "Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF, Kiaei M. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011;51(1):88\u201396.", "ArticleIdList": ["PMC3109235", "21457778"]}, {"Citation": "Bocci V. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res. 2006;37(4):425\u2013435.", "ArticleIdList": ["16624639"]}, {"Citation": "Yildrim Z, Ucgun NI, Yildrim F. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. Clinics (Sao Paulo) 2011;66(5):743\u2013746.", "ArticleIdList": ["PMC3109369", "21789374"]}, {"Citation": "Bocci V. How a calculated oxidative stress can yield multiple therapeutic effects. Free Radic Res. 2012;46(9):1068\u20131075.", "ArticleIdList": ["22583557"]}]}], "History": [{"Year": "2012", "Month": "4", "Day": "8"}, {"Year": "2012", "Month": "11", "Day": "5"}, {"Year": "2013", "Month": "1", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "1", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "1", "Day": "1", "Hour": "6", "Minute": "1"}, {"Year": "2012", "Month": "12", "Day": "18"}], "PublicationStatus": "ppublish", "ArticleIdList": ["23275905", "PMC3530813", "10.3980/j.issn.2222-3959.2012.06.11", "ijo-05-06-708"]}}], "PubmedBookArticle": []}